Osmetech PLC Idexx Molecular Sensing
Interim Results for this Atlanta based company are to be published
on 27th January and are expected to contain a few surprises.
James White, CEO of Osmetech said:
"We have a high quality operational infrastructure capable of supporting the continued growth of the business. We expect to beable to build on the excellent performance of OPTI this year and are confident of significant growth commencing in the second half of next year through the new product introductions and the IDEXX relationship."
Gordon Hall, Chairman of Osmetech said:
"The first full year of trading of the OPTI product line has exceeded our expectations at all levels. This business provides a sound and profitable commercial base for the Group. There are clear organic growth plans for OPTI which will commence in the second half of the coming financial year following the launch of three key new products and the start of the important trading relationship with IDEXX in the veterinary market."
VET-STAT was launched at the North American Veterinary Conference and is the first product to reach the market following the OEM and supply agreement made with Idexx in August 2004. Potential revenues from the Idexx deal could be substantially equivalent to those generated by Opti with in 2 years.
James White, CEO of Osmetech said:
"The long term commercial relationship with IDEXX should provide a substantial level of new business for OPTI both in terms of instrument sales and ongoing revenues derived from sales of our proprietary consumables."
Michael Williams DVP, Chemistry General Manager of Idexx said:
"We're very excited about the addition of this product to our integrated VetLab suite of in-clinic diagnostic instruments."
http://bestinvest.uk-wire.com/cgi-bin/articles/200408060700086991B.html
James White, CEO of Osmetech plc said:
"We are delighted to be acquiring the Molecular Sensing business. The genedrive product gives us a strong entry point into the fastest growing market segment of DNA based diagnostics.
We believe that combining the genedrive platform with LGC Limited's HyBeacon chemistry will provide us with a powerful complete diagnostic test format that should enable us to successfully attack many of the clear market opportunities in the near patient settings. These important markets include sexually transmitted disease testing, genetic testing and macogenomics.
We also intend to exploit licensing opportunities for the technology as well as exploring the possibility of commercial partnerships as a means of providing revenues in markets other than healthcare diagnostics.
This acquisition is another step in transforming Osmetech from a technology company with potential into a rapidly developing international diagnostics company operating in high-growth market sectors."
Mols RNS
OPTI-CCA Comfort Sampler CONSUMABLE Datatrol
Genedrive VIP 5 OPTI IV OMA-UTI
Osmetech : The Next Generation - Info and Links thread.
I think most of us have been stiched up by EVO and the MM's games over the last couple of years, the real enemy is not each other it is EVO and the MM's. They are the fools we need to be making money off rather than giving it to them. This share needs people with balls of steel, you have to ride out the rough with the smooth, the ups and down and the pumps and dumps.
Study the company, look long and hard at what they are doing and how they are doing it. Look at the way Osmetech has transformed itself in the last 18 months. Look at the fundementals, look at the potential market for their products look at what the management have done to safe guard the long term future of the company.
Buying OPTI and MOLS were a strokes of genius and the company is still looking for similar deals. Despite all the knockers both on here and III Jimmy boy and co have done a great job stream lining the company and getting it focussed.
VIP5 and GENEDRIVE are going to be the real cash cows are a within 12 months of being launched. Osmetech will then have dipped two toes into a two multi billion dollar markets. By listening to the derampers and the notsoHOT pump and dump merchants now you could be kicking yourself in 18 months time.
Buy your shares and hold the bloody things. Don't sell them back to EVO at the first sign of a tree shake. EVO are well aware of what the future holds, why would they have backed Osmo financially if they did not? EVO will be hanging in to the glory days and so should you.
Become a TRUE INVESTOR Buy your thousand quids worth of shares and hold on to them through thick and thin.
18 Months from now I am sure you will be more than amply rewarded.
Have you got balls of steel or testicals of tissue?
Study the company, look long and hard at what they are doing and how they are doing it. Look at the way Osmetech has transformed itself in the last 18 months. Look at the fundementals, look at the potential market for their products look at what the management have done to safe guard the long term future of the company.
Buying OPTI and MOLS were a strokes of genius and the company is still looking for similar deals. Despite all the knockers both on here and III Jimmy boy and co have done a great job stream lining the company and getting it focussed.
VIP5 and GENEDRIVE are going to be the real cash cows are a within 12 months of being launched. Osmetech will then have dipped two toes into a two multi billion dollar markets. By listening to the derampers and the notsoHOT pump and dump merchants now you could be kicking yourself in 18 months time.
Buy your shares and hold the bloody things. Don't sell them back to EVO at the first sign of a tree shake. EVO are well aware of what the future holds, why would they have backed Osmo financially if they did not? EVO will be hanging in to the glory days and so should you.
Become a TRUE INVESTOR Buy your thousand quids worth of shares and hold on to them through thick and thin.
18 Months from now I am sure you will be more than amply rewarded.
Have you got balls of steel or testicals of tissue?
LemmingInvestor
Junior member
- Messages
- 18
- Likes
- 1
OMH took another hit as investors took fright on a near doubling of losses. However, short sighted as it may seem to those who know the company well, you could make an argument to buying opp for the longer term when new revenues come on stream.
I will be updating OMH over the next couple of days.
I will be updating OMH over the next couple of days.
LemmingInvestor
Junior member
- Messages
- 18
- Likes
- 1
There have been several significant developments since I started this thread.
Osmetech are now selling the AVOXIMETER 4000 worldwide (- USA) in a deal with AVOX.
Roche have licensed the plastic tubing technology Osmetech acquired as part of their purchase of Molecular Sensing Ltd.
UTI would appear to be more or less dead though the BV e-nose may have some life left in it yet.
The deal with Idexx to supply OPTI-CCA machines as VETSTAT is progressing better than expected with IDEXX have landed a contract to supply a leading American national vetinary hospital chain. 450 additional VETSTAT machines are required to fulfil this deal.
The company have issued a trading update announcing sales are up 4% on last year and that they have now opened a sales department in Germany.
GENEDRIVE has been re-branded as OPTi-GENE and is to be displayed both here and in America in November and then there is the yet to be formally announced OPTI -LION, a device to measure electrolyte and pH analytes.
Better get my finger out and get this thread updated.
Osmetech are now selling the AVOXIMETER 4000 worldwide (- USA) in a deal with AVOX.
Roche have licensed the plastic tubing technology Osmetech acquired as part of their purchase of Molecular Sensing Ltd.
UTI would appear to be more or less dead though the BV e-nose may have some life left in it yet.
The deal with Idexx to supply OPTI-CCA machines as VETSTAT is progressing better than expected with IDEXX have landed a contract to supply a leading American national vetinary hospital chain. 450 additional VETSTAT machines are required to fulfil this deal.
The company have issued a trading update announcing sales are up 4% on last year and that they have now opened a sales department in Germany.
GENEDRIVE has been re-branded as OPTi-GENE and is to be displayed both here and in America in November and then there is the yet to be formally announced OPTI -LION, a device to measure electrolyte and pH analytes.
Better get my finger out and get this thread updated.
